Terumo

Terumo FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Terumo (4543.T) as of Nov 5, 2026 is 107.16 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 121.55 % — a change of -11.84% (lower).

FCF Conversion

107.16 %

YoY

-11.84%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Terumo is 2026 107.16 % . FCF Conversion Rate (FCF/EBITDA) of Terumo was 2025 121.55 % . It decreases by -11.84% lower compared to the previous year.

The Terumo FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
68.26 JPY
Jan 1, 2020
39.90 JPY
Jan 1, 2021
49.65 JPY
Jan 1, 2022
75.85 JPY
Jan 1, 2023
50.78 JPY
Jan 1, 2024
80.47 JPY
Jan 1, 2025
121.55 JPY
Jan 1, 2026
107.16 JPY
The Terumo FCF Conversion history
YEARFCF ConversionYoY
107.16 %-11.84%
121.55 %+51.04%
80.47 %+58.46%
50.78 %-33.04%
75.85 %+52.77%
49.65 %+24.44%
39.90 %-41.55%
68.26 %-24.64%
90.58 %-3.74%
94.10 %-8.46%
102.80 %+10.56%
92.98 %-43.72%
165.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Terumo Stock analysis

What does Terumo do? Terumo Corporation is a Japanese company that was founded in 1921. The company is headquartered in Tokyo and specializes in the development, manufacturing, and marketing of medical products and devices. It has a global presence and employs approximately 28,000 people in over 160 countries. The company's history began with the establishment of a small medical device company called Sekisen Kenonsha, founded by a group of doctors. In 1942, the company merged with another company named Terumo Sougou Kenkyuusho and became Terumo Corporation. Since then, the company has continuously expanded and diversified its product range. Terumo's business model focuses on providing solutions to improve people's health worldwide through the development of innovative medical devices and products. The company operates in three main business areas: 1. Interventional Systems: This business area specializes in the development of catheters, stent systems, and other medical products for cardiac, peripheral, and vascular interventions. 2. Blood Systems: This business area offers a wide range of products for blood collection and processing, including disposable syringes for blood collection and venous and arterial access systems. 3. Biosciences: This business area focuses on the development of products for cell culture and regenerative medicine, including stem cell therapy and cell banks for research. Terumo distributes its products not only directly to hospitals and medical facilities but also collaborates closely with distributors and partners to reach a wider customer base. Additionally, the company invests significant resources in research and development to continuously expand its product range. Among the products that Terumo offers, some of the most advanced and innovative medical devices on the market can be found. One example is the state-of-the-art catheters and stent systems that enable doctors to perform minimally invasive procedures to treat serious cardiovascular diseases. Terumo also produces disposable syringes that are widely used due to their high quality and reliability. In recent years, Terumo has also invested in regenerative medicine by developing products for cell culture and therapy. This includes stem cell therapy products that can be used in the treatment of certain cancers and blood disorders. Overall, Terumo Corporation has a long history as one of the leading companies in the medical technology industry. With its innovative products and strong focus on research and development, the company will continue to play an important role in improving the health and well-being of people worldwide. Terumo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Terumo stock

FCF Conversion Rate (FCF/EBITDA) of Terumo is 107.16 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Terumo changed from 121.55 % to 107.16 %, representing a -11.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Terumo since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Terumo with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Terumo

All Key Metrics — Terumo